AZN vs LMAT
ASTRAZENECA PLC vs LEMAITRE VASCULAR INC — Side-by-Side Stock Comparison
AZN
ASTRAZENECA PLC
8.4
Strong Buy
$200.99
LMAT
LEMAITRE VASCULAR INC
6.4
Consider Buy
$108.96
AZN vs LMAT: Which is the Better Investment?
ASTRAZENECA PLC (AZN) scores 8.4/10 while LEMAITRE VASCULAR INC (LMAT) scores 6.4/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, ASTRAZENECA PLC trades at 30.4x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | AZN | LMAT |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 8.4/10▲ | 6.4/10 |
| Rating | Strong Buy▲ | Consider Buy |
| Price | $200.99 | $108.96 |
| P/E Ratio | 30.4▲ | 43.3 |
| ROE | 21.9%▲ | 14.9% |
| Market Cap | $312B | $2B |
| Fair Value | $192.63 | $67.42 |
| Dividend Yield | 1.6%▲ | 0.7% |
| Sector Rank | #3 of 1127▲ | #201 of 1127 |
| Model Verdicts | ||
| Piotroski | Strong▲ | Attractive |
| Buffett | Strong▲ | Attractive |
| Graham | Caution | Neutral▲ |
| Lynch | Neutral | Neutral |
| Greenblatt | Neutral▲ | Caution |
AZN vs LMAT: Which Stock Scores Higher?
ASTRAZENECA PLC (AZN) and LEMAITRE VASCULAR INC (LMAT) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to LMAT's 6.4/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer